FDA approves Clovis’ flagship drug for prostate cancer treatment

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) received approval from federal drug regulators to sell its Rubraca treatment for use in prostate-cancer patients.

The Boulder pharmaceutical company said the drug will be available to prostate cancer patients who haven’t responded to chemotherapy or other existing forms of treatment. The drug was given priority review status in January for an Phase III trial in patients.

“We are pleased that the FDA has granted an accelerated approval for Rubraca in this third indication,” CEO Patrick Mahaffy said in a statement.

SPONSORED CONTENT

The many benefits of simple, coordinated healthcare

Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.

Rubraca, which was originally approved for use in 2016 for treating advanced ovarian cancer, is the only product Clovis has greenlit for sale. The company sold $143 million worth of Rubraca in 2019, a $47 million increase from the previous year.

Christopher Wood

Christopher Wood is editor and publisher of BizWest, a regional business journal covering Boulder, Broomfield, Larimer and Weld counties. Wood co-founded the Northern Colorado Business Report in 1995 and served as publisher of the Boulder County Business Report until the two publications were merged to form BizWest in 2014. From 1990 to 1995, Wood served as reporter and managing editor of the Denver Business Journal. He is a Marine Corps veteran and a graduate of the University of Colorado Boulder. He has won numerous awards from the Colorado Press Association, Society of Professional Journalists and the Alliance of Area Business Publishers.